Publications
2024
Scholarly publications
van Hattem, C. C., de Jong, A. J., de Groot, J. S., Hoekman, J., Broekman, K. E., Sonke, G. S., van Hennik, P. B., & Bloem, L. T. (2024). Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study. BMJ Open, 14, Article e084483. https://doi.org/10.1136/bmjopen-2024-084483
Zinken, J. F., Pasmooij, A. M. G., Ederveen, A. G. H., Hoekman, J., & Bloem, L. T. (2024). Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role. Drug Discovery Today, 29(12), Article 104213. Advance online publication. https://doi.org/10.1016/j.drudis.2024.104213
Kienhuis, A., Krul, C., van Engelen, J., Evelo, C. T., Hessel, E., Hoekman, J., Kramer, N., Krop, E., Masereeuw, R., Moors, E., Negro, S. O., Piersma, A., Pieters, R., Teunis, M., Willighagen, E., & Legler, J. (2024). The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data. Altex. Advance online publication. https://doi.org/10.14573/altex.2407211
Hoogstraaten, M. J., Vriend, J., de Leeuw, V. C., Negro, S. O., Moors, E. H. M., Kienhuis, A. S., & Hoekman, J. (2024). Animal-free safety assessment of chemicals: an innovation system perspective. Archives of Toxicology. Advance online publication. https://doi.org/10.1007/s00204-024-03878-0
Wijne, T., Moors, E., Boon, W., & Hoekman, J. (2024). Creating societal impact through impact practices in large-scale trandisciplinary research projects. Paper presented at EASST-4S 2024 Conference, Amsterdam, Netherlands.
van de Voort, T., Moors, E., Hoekman, J., & Bloem, L. T. (2024). Understanding the transformative nature of initiatives challenging the traditional pharmaceutical model in the gene and cell therapy field. Abstract from EASST-4S 2024 Conference, Amsterdam, Netherlands.
Kleinhout-Vliek, T. H., Boon, W. P. C., Hagendijk, R. P., Hoekman, J., & Moors, E. H. M. (2024). Together for the greater goods: legitimising social innovation in the pharmaceutical field. Innovation: The European Journal of Social Science Research, 37(1), 60-84. https://doi.org/10.1080/13511610.2024.2305908
Hoekman, J., & Rake, B. (2024). Geography of authorship: How geography shapes authorship attribution in big team science. Research Policy, 53(2), Article 104927. https://doi.org/10.1016/j.respol.2023.104927
2023
Scholarly publications
Hoogstraaten, M., Negro, S., Moors, E., Kienhuis, A., de Leeuw, V., Vriend, J., & Hoekman, J. (2023). Analyzing and accelerating the transition towards safety testing of chemical substances through new approach methodologies. Abstract from International Sustainability Transitions Conference, Utrecht, Netherlands.
Kuipers-Dirven, R., Janssen, M., & Hoekman, J. (2023). Assessing university policies for enhancing societal impact of academic research: A multicriteria mapping approach. Research Evaluation, 32(2), 371-383. https://doi.org/10.1093/reseval/rvac045
Punt, M., van Kollem, J., Hoekman, J., & Frenken, K. (2023). Your Uber is arriving now: An analysis of platform location decisions through an institutional lens. Strategic Organization, 21(3), 501–536. https://doi.org/10.1177/14761270211022254
Professional publications
European Commission, Directorate-General for Health and Food Safety, Mantel - Teeuwisse, A., Bloem, L. T., Boon, W., De Bruin, M. L., Hoekman, J., Klein, K., Stolk, P., & Vreman, R. (2023). Study in support of the evaluation and impact assessment of the EU general pharmaceuticals legislation: Analytical Report. Publications Office of the European Union. https://doi.org/10.2875/780874
European Commission, Directorate-General for Health and Food Safety, Mantel - Teeuwisse, A., Bloem, L. T., Boon, W., De Bruin, M. L., Hoekman, J., Klein, K., Stolk, P., & Vreman, R. (2023). Study in support of the evaluation and impact assessment of the EU general pharmaceuticals legislation: Evaluation Report. Publications Office of the European Union. https://doi.org/10.2875/62709
2022
Scholarly publications
Janssen, M., Hoekman, J., & Kuipers, R. (2022). Towards Science for Society: A multicriteria mapping study on university policies for enhancing societal impact of Dutch academic research. Research Evaluation.
Kleinhout - Vliek, T., Boon, W., Hagendijk, R., Hoekman, J., & Moors, E. (2022). Causing headwinds? How Dutch actors conceive situated futures for magistral preparation of pharmaceuticals. Abstract from EASST 2022 (European Association for the Study of Science and Technology) , Madrid, Spain.
Douglas, C., Aith, F., Cordovil-Oliveira, C., Boon, W., Doganova, L., Hagendijk, R., Hoekman, J., Kleinhout - Vliek, T., Moors, E., Mallard, A., Paterson, F., Grunebaum, S., & Rabeharisoa, V. (2022). Social pharmaceutical innovation: Towards a interdisciplinary research agenda for drugs for rare diseases. Abstract from EU-SPRI Conference 2022, Utrecht, Netherlands.
Kleinhout - Vliek, T., Boon, W., Hagendijk, R., Hoekman, J., & Moors, E. (2022). Legitimising Dutch Social Pharmaceutical Innovation. Abstract from EU-SPRI Conference 2022, Utrecht, Netherlands.
Leufkens, H. G., Kusynová, Z., Aitken, M., Hoekman, J., Stolk, P., Klein, K., & Mantel-Teeuwisse, A. K. (2022). Four scenarios for the future of medicines and social policy in 2030. Drug Discovery Today, 27(8), 2252-2260. https://doi.org/10.1016/j.drudis.2022.03.018
ten Ham, R. M. T., Frederix, G. W. J., Wu, O., Goettsch, W., Leufkens, H. G. M., Klungel, O. H., & Hoekman, J. (2022). Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. Value in Health, 25(3), 390-399. https://doi.org/10.1016/j.jval.2021.09.012
Bloem, L. T., Bot, R. E., Mantel-Teeuwisse, A. K., van der Elst, M. E., Sonke, G. S., Klungel, O. H., Leufkens, H. G. M., & Hoekman, J. (2022). Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology, 88(5), 2169-2179. https://doi.org/10.1111/bcp.15141
Vreman, R. A., Bloem, L. T., van Oirschot, S., Hoekman, J., van der Elst, M. E., Leufkens, H. G., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2022). The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 11(5), 642-650. https://doi.org/10.34172/ijhpm.2020.198
2021
Scholarly publications
Hoekman, J., & Rake, B. (2021). Geography of authorship: determinants of authorship in global team science. Abstract from Eu-SPRI Annual Conference 2021, Oslo, Norway.
Kuipers, R., Janssen, M., & Hoekman, J. (2021). Towards Science for Society: A multicriteria mapping study on university policies to enhance societal impact of Dutch academic research. Abstract from Eu-SPRI Annual Conference 2021, Oslo, Norway.
Kleinhout - Vliek, T., Arentshorst, M., Kalkman, S., Boon, W., Hagendijk, R., Hoekman, J., & Moors, E. (2021). Causing headwinds? How Dutch actors conceive situational futures for magistral preparation of pharmaceuticals. Paper presented at Society for Social Studies of Science (4S) 2021 Annual meeting, "Virtual Toronto".
Bloem, L. T., Karomi, M., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., & Mantel-Teeuwisse, A. K. (2021). Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle–a focus on benefits and risks. Expert Opinion on Drug Safety, 20(11), 1433-1442. https://doi.org/10.1080/14740338.2021.1952981
van Hunsel, F., de Jong, E., Gross-Martirosyan, L., & Hoekman, J. (2021). Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions. Pharmacoepidemiology and Drug Safety, 30(8), 1115-1122. https://doi.org/10.1002/pds.5246
Bloem, L. T., Vreman, R. A., Peeters, N. W. L., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2021). Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 14(4), 1566-1577. https://doi.org/10.1111/cts.13027
ten Ham, R. M. T., Nievaart, J. C., Hoekman, J., Cooper, R. S., Frederix, G. W. J., Leufkens, H. G. M., Klungel, O. H., Ovelgönne, H., Hoefnagel, M. H. N., Turner, M. L., & Mountford, J. C. (2021). Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy, 23(8), 730-739. https://doi.org/10.1016/j.jcyt.2020.12.014
Minnema, L. A., Giezen, T. J., Hoekman, J., Egberts, T. C. G., Leufkens, H. G. M., & Gardarsdottir, H. (2021). Regulatory safety learning driven by the mechanism of action: the case of TNF-α inhibitors. Clinical Pharmacology and Therapeutics, 110(1), 123-131. https://doi.org/10.1002/cpt.2127
Professional publications
Boon, W., Verkade, N., Hoekman, J., van der Voort, T., & Moors, E. (2021). Innovation pathways to achieve the moonshot for proof-of-concept therapy for type 1 diabetes. (deliverable 5.3 ‘adapted ELSA’ ed.) RegMed XB .
2020
Scholarly publications
Coppens, D. G., Gardarsdottir, H., Bruin, M. L. D., Meij, P., Gm Leufkens, H., & Hoekman, J. (2020). Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. Regenerative Medicine, 15(8), 2015-2028. https://doi.org/10.2217/rme-2020-0008
https://dspace.library.uu.nl/bitstream/handle/1874/428437/rme_2020_0008.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/428437/rme_2020_0008.pdf?sequence=1
Wuestman, M., Hoekman, J., & Frenken, K. (2020). A typology of scientific breakthroughs. Quantitative Science Studies, 1(3), 1203-1222. https://doi.org/10.1162/qss_a_00079
Coppens, D. G. M., Hoekman, J., De Bruin, M. L., Slaper-Cortenbach, I. C. M., Leufkens, H. G. M., Meij, P., & Gardarsdottir, H. (2020). Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Cytotherapy, 22(10), 592-600. https://doi.org/10.1016/j.jcyt.2020.04.092
Ten Ham, R. M. T., Hövels, A. M., Hoekman, J., Frederix, G. W. J., Leufkens, H. G. M., Klungel, O. H., Jedema, I., Veld, S. A. J., Nikolic, T., Van Pel, M., Zwaginga, J. J., Lin, F., de Goede, A. L., Schreibelt, G., Budde, S., de Vries, I. J. M., Wilkie, G. M., Dolstra, H., Ovelgönne, H., ... Hoefnagel, M. H. N. (2020). What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 22(7), 388-397. https://doi.org/10.1016/j.jcyt.2020.03.432
Coppens, D. G., Gardarsdottir, H., van den Bogert, C. A., De Bruin, M. L., Leufkens, H. G., & Hoekman, J. (2020). Publication rates and reported results in a cohort of gene- and cell-based therapy trials. Regenerative Medicine, 15(1), 1215-1227. https://doi.org/10.2217/rme-2019-0066
Ten Ham, R. M. T., Hövels, A. M., Klungel, O. H., Leufkens, H. G. M., Broekmans, A. W., & Hoekman, J. (2020). Development and regulation of gene and cell-based therapies in Europe: a quantification and reflection. Trends in Pharmacological Sciences, 41(2), 67-71. https://doi.org/10.1016/j.tips.2019.11.007
Kalkman, S., Arentshorst, M., Hoekman, J., Boon, W., Uijtendaal, E., van Thiel, G., & Moors, E. (2020). In-Hospital Production of Medicines: Preparing for Disruption. Trends in Biotechnology, 38(10), 1045-1047. https://doi.org/10.1016/j.tibtech.2019.09.011
Bignami, F., Mattsson, P., & Hoekman, J. (2020). The importance of geographical distance to different types of R&D collaboration in the pharmaceutical industry. Industry and Innovation, 27(5), 513-537. https://doi.org/10.1080/13662716.2018.1561361
2019
Scholarly publications
Hoekman, J. (2019). Emerging risks over the technological life-cycle: Effects of novelty on the detection of technological risks. Paper presented at European Meeting on Applied Evolutionary Economics 2019 (EMAEE)
, Brighton, United Kingdom.
, Brighton, United Kingdom.
Boon, W. P. C., Hollants, B., van den Berg, S., Schuurmans, E., & Hoekman, J. (2019). Kennisagenda zeldzame ziekten: Multi-stakeholder expertstudie naar kennisprioriteiten. Utrecht University.
https://dspace.library.uu.nl/bitstream/handle/1874/394481/uu_2019_kennisagenda_zeldzame_ziekten_finale_versie.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/394481/uu_2019_kennisagenda_zeldzame_ziekten_finale_versie.pdf?sequence=1
Wuestman, M. L., Hoekman, J., & Frenken, K. (2019). The geography of scientific citations. Research Policy, 48(7), 1771-1780. https://doi.org/10.1016/j.respol.2019.04.004
Bloem, L. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., De Bruin, M. L., Klungel, O. H., & Hoekman, J. (2019). Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. Clinical Pharmacology and Therapeutics, 105(2), 426-435. https://doi.org/10.1002/cpt.1169
Hoekman, J., & Boon, W. (2019). Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union. Social Science & Medicine, 222, 76-83. https://doi.org/10.1016/j.socscimed.2018.12.025
2018
Scholarly publications
ten Ham, R. M., Hovels, A. M., Hoekman, J., Broekmans, A., Leufkens, H. G., & Klungel, O. (2018). CHALLENGES IN ACHIEVING MARKET ACCESS SUCCESS FOR ADVANCED THERAPIES IN EUROPE: A CASE STUDY. In ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems (pp. 213) https://doi.org/10.1016/j.jval.2018.09.2868
Jacobs, T. G., Hilda Ampadu, H., Hoekman, J., Dodoo, A. N. O., & Mantel-Teeuwisse, A. K. (2018). The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health, 18(1), Article 1384. https://doi.org/10.1186/s12889-018-6285-9
Hilda Ampadu, H., Hoekman, J., Arhinful, D., Amoama-Dapaah, M., Leufkens, H. G. M., & Dodoo, A. N. O. (2018). Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. Globalization and Health, 14(1), Article 109. https://doi.org/10.1186/s12992-018-0431-0
ten Ham, R. M. T., Hoekman, J., Hövels, A. M., Broekmans, A. W., Leufkens, H. G. M., & Klungel, O. H. (2018). Challenges in Advanced Therapy Medicinal Products Development: A survey amongst companies in Europe. Molecular Therapy - Methods & Clinical Development, 11, 121-130. https://doi.org/10.1016/j.omtm.2018.10.003
Coppens, D. G. M., de Wilde, S., Guchelaar, H. J., De Bruin, M. L., Leufkens, H. G. M., Meij, P., & Hoekman, J. (2018). A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. Cytotherapy, 20(6), 769-778. https://doi.org/10.1016/j.jcyt.2018.03.038
de Wilde, S., Coppens, D. G. M., Hoekman, J., de Bruin, M. L., Leufkens, H. G. M., Guchelaar, H.-J., & Meij, P. (2018). EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. Drug Discovery Today, 23(7), 1328-1333. https://doi.org/10.1016/j.drudis.2018.03.008
Coppens, D. G. M., De Bruin, M. L., Leufkens, H. G. M., & Hoekman, J. (2018). Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation. Clinical Pharmacology and Therapeutics, 103(1), 120-127. https://doi.org/10.1002/cpt.894
Other output
Moors, E. H. M., Arentshorst, M. E., Boon, W. P. C., & Hoekman, J. (2018). Transition to distributed sustainable innovation models. Paper presented at 9th International Sustainability Transitions Conference (IST) 2018, Manchester, United Kingdom.
2017
Scholarly publications
Moors, E. H. M., Hoekman, J., Kalkman, S., Arentshorst, M. E., Boon, W. P. C., & van Thiel, G. (2017). From mass to modular innovation. Towards distributed drug development models. Paper presented at International workshop on medical innovation (WOMI 2017), Reykjavik, Iceland.
Hoekman, J. (2017). Learning to identify safety risks of medical technologies. Paper presented at International workshop on medical innovation (WOMI 2017), Reykjavik, Iceland.
de Wilde, S., Coppens, D., De Bruin, M. L., Leufkens, H. G., Guchelaar, H. J., Hoekman, J., & Meij, P. (2017). Decision-making on marketing authorization of advanced therapy medicinal products in the European union. Cytotherapy, 19(5), S63. https://doi.org/10.1016/j.drudis.2018.03.008
Coppens, D., DeWilde, S., Guchelaar, H. J., De Bruin, M., Leufkens, H., Meij, P., & Hoekman, J. (2017). Decision-making for marketing approval of cell and gene based therapy products in the European union, United States and Canada. Cytotherapy, 19(5), S62-S63. https://doi.org/10.1016/j.jcyt.2017.02.144
Boon, W. P. C., Evers, G. W., & Hoekman, J. (2017). Research-based innovation activities on rare diseases in the Netherlands. Utrecht University / ZonMW.
Frenken, K., Heimeriks, G. J., & Hoekman, J. (2017). What drives university research performance? An analysis using the CWTS Leiden Ranking data. Journal of Informetrics, 11(3), 859-872. https://doi.org/10.1016/j.joi.2017.06.006
Liberti, L., Bujar, M., Breckenridge, A., Hoekman, J., McAuslane, N., Stolk, P., & Leufkens, B. (2017). FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Frontiers in Pharmacology, 8, 1-6. Article 161. https://doi.org/10.3389/fphar.2017.00161
Liberti, L., Breckenridge, A., Hoekman, J., McAuslane, N., Stolk, P., & Leufkens, B. (2017). Factors related to drug approvals: predictors of outcome? Drug Discovery Today, 22(6), 937-946. https://doi.org/10.1016/j.drudis.2017.03.003
Other output
Shakir, S., Bloem, L., Bruin, M. L. D., Hoekman, J., Leufkens, H., & Ryan, P. (2017). Practical Points to Address Uncertainties in Risk Management Planning.
Bloem, L. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., De Bruin, M. L., Klungel, O. H., & Hoekman, J. (2017). Risk factors associated with post-marketing changes in specific obligations of conditionally authorised products in the EU. Pharmacoepidemiology and Drug Safety, 26, 605. https://doi.org/10.1002/pds.4275
Boon, W. P. C., Hoekman, J., Moors, E. H. M., & Evers, G. W. (2017). Innovation for rare diseases – co-creation in innovation ecosystems in the Netherlands. Paper presented at Eu-SPRI Annual Conference 2017, Vienna, Austria.
2016
Scholarly publications
Liberti, L., Breckenridge, A., Hoekman, J., Leufkens, B., Lumpkin, M., McAuslane, N., Stolk, P., Zhi, K., & Rägo, L. (2016). Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities. Journal of Public Health Policy, 37(3), 315-333. https://doi.org/10.1057/jphp.2016.8
Hoekman, J., Klamer, T. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & De Bruin, M. L. (2016). Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. British Journal of Clinical Pharmacology, 82(1), 213-226. https://doi.org/10.1111/bcp.12940
Ampadu, H. H., Hoekman, J., de Bruin, M. L., Pal, S. N., Olsson, S., Sartori, D., Leufkens, H. G. M., & Dodoo, A. N. O. (2016). Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase(®). Drug Safety. https://doi.org/10.1007/s40264-015-0387-4
Schievink, B., de Zeeuw, D., Smink, P. A., Andress, D., Brennan, J. J., Coll, B., Correa-Rotter, R., Hou, F. F., Kohan, D., Kitzman, D. W., Makino, H., Parving, H.-H., Perkovic, V., Remuzzi, G., Tobe, S., Toto, R., Hoekman, J., & Lambers Heerspink, H. J. (2016). Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 23, 758-768. https://doi.org/10.1177/2047487315598709
Other output
Hoekman, J., & Boon, W. P. C. (2016). Constructing regulatory niches for medicines that address unmet needs. Abstract from 2016 Eu-SPRI Conference “Exploring New Avenues for Innovation and Research Policies, Lund, Sweden.
2015
Scholarly publications
De Bruin, M. L., Ampadu, H. H., Hoekman, J., Kurz, X., Leufkens, H. G. M., Sekine, S., & Pan, G. D. (2015). Data driven regulatory science. Pharmacoepidemiology and Drug Safety, 24(S1), 46. https://doi.org/10.1002/pds.3838
Hoekman, J., Boon, W., Bouvy, J. C., Ebbers, H. C., de Jong, J. P., & De Bruin, M. L. (2015). Use of the conditional marketing authorization pathway for oncology medicines in Europe. Clinical Pharmacology and Therapeutics, 98(5), 534-541. https://doi.org/10.1002/cpt.174
Lipska, I., Hoekman, J., McAuslane, N., Leufkens, H., & Hövels, A. M. (2015). Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions? Clinical Pharmacology and Therapeutics, 98(5), 489-491. https://doi.org/10.1002/cpt.198
Heerspink, H. J. L., Kröpelin, T. F., Hoekman, J., & De Zeeuw, D. (2015). Drug-induced reduction in albuminuria is associated with subsequent renoprotection: A meta-analysis. Journal of the American Society of Nephrology, 26(8), 2055-2064. https://doi.org/10.1681/ASN.2014070688
Ebbers, H. C., Langedijk, J., Bouvy, J. C., Hoekman, J., Boon, W. P. C., de Jong, J. P., & De Bruin, M. L. (2015). An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe. European Journal of Clinical Pharmacology, 71(10). https://doi.org/10.1007/s00228-015-1904-1
Other output
De Bruin, M., Ampadu, H. H., Hoekman, J., Kurz, X., Leufkens, H., Sekine, S., & Dal Pan, G. (2015). Data driven regulatory science. Abstract from 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPT), Boston, USA, Boston, United States.
Hoekman, J., & Boon, W. P. C. (2015). Balancing uncertainty and unmet need in pharmaceutical early access programs. 77. Abstract from The 24the Society for Risk Analysis Europe Conference, Maastricht, Netherlands.
2014
Scholarly publications
Boon, W. P. C., Bouvy, J. C., Broekmans, A. W., de Bruin, M. L., Ebbers, H. C., Hoekman, J., de Jong, J. P., Koopmanschap, M. A., Langedijk, J., & Stolk, P. (2014). Improving the EU system for the marketing authorisation of medicines: Learning from regulatory practice. Escher – The TI Pharma Platform for Regulatory Innovation. http://escher.lygature.org/fileadmin/media-archive/escher/Reports/Escher_report_IA.pdf
Smink, PA., Hoekman, J., Grobbee, DE., Eijkemans, MJC., Parving, H.-H., Persson, F., Ibsen, H., Lindholm, L., Wachtell, K., de Zeeuw, D., & Heerspink, HJ. L. (2014). A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 21(4), 434-444. https://doi.org/10.1177/2047487313481754
Smink, P. A., Miao, Y., Eijkemans, M. J. C., Bakker, S. J. L., Raz, I., Parving, H.-H., Hoekman, J., Grobbee, D. E., de Zeeuw, D., & Lambers Heerspink, H. J. (2014). The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers. Clinical Pharmacology and Therapeutics, 95(2), 208-215. https://doi.org/10.1038/clpt.2013.191
Frenken, K., & Hoekman, J. (2014). Spatial Scientometrics and Scholarly Impact: A Review of Recent Studies, Tools, and Methods. In Y. Ding, R. Rousseau, & D. Wolfram (Eds.), Measuring Scholarly Impact: Methods and Practice (pp. 127-146). Springer. https://doi.org/10.1007/978-3-319-10377-8_6
Schievink, B., Heerspink, H. L., Leufkens, B., De Zeeuw, D., & Hoekman, J. (2014). The use of surrogate endpoints in regulating medicines for cardio-renal disease: Opinions of stakeholders. PLoS One, 9(9), Article e108722. https://doi.org/10.1371/journal.pone.0108722
Hoekman, J., Lambers Heerspink, H. J., Viberti, G., Green, D., Mann, J. F. E., & de Zeeuw, D. (2014). Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clinical Journal of the American Society of Nephrology, 9(3), 490-8. https://doi.org/10.2215/CJN.07040713
Other output
Kurz, X., Martin, D., Hoekman, J., Bouvy, J. C., Roddam, A., Ebbers, H., Leufkens, H. G. M., Chan, K. A., Dal Pan, G., Reynolds, R., & De Bruin, M. L. (2014). Challenges in implementing findings of regulatory science to evaluate and improve the drug regulatory system. Pharmacoepidemiology and Drug Safety, 23(S1), 204-205. https://doi.org/10.1002/pds.3701
Bouvy, J. C., De Bruin, M. L., Hoekman, J., & Stolk, P. (2014). The costs and effects of post-authorisation safety studies for new active substances. Value in Health, 17(7), 445-446. https://doi.org/10.1016/j.jval.2014.08.1184
2013
Scholarly publications
Rafols, I., Hopkins, M. M., Hoekman, J., Siepel, J., O'Hare, A., Perianes-Rodriguez, A., & Nightingale, P. (2013). Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline. arXiv.org, 1306, 947. https://doi.org/10.1016/j.techfore.2012.06.007
Hoekman, J., & Frenken, K. (2013). Proximity and Stratification in European Scientific Research Collaboration Networks: A Policy Perspective. In T. Scherngell (Ed.), Advances in Spatial Science: The Geography of Networks and R&D Collaborations (pp. 263-277). Springer. https://doi.org/10.1007/978-3-319-02699-2_14
https://dspace.library.uu.nl/bitstream/handle/1874/429795/isu1304.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/429795/isu1304.pdf?sequence=1
Hoekman, J., Scherngell, T., Frenken, K., & Tijssen, R. (2013). Acquisition of European research funds and its effect on international scientific collaboration. Journal of Economic Geography, 13(1), 23-52. Article lbs011. https://doi.org/10.1093/jeg/lbs011
2012
Scholarly publications
Hoekman, J., Frenken, K., de Zeeuw, D., & Lambers-Heerspink, H. J. (2012). The Geographical Distribution of Leadership in Globalized Clinical Trials. PLoS One, 7(10), 1-7. Article e45984. https://doi.org/10.1371/journal.pone.0045984
2011
Scholarly publications
Vinciguerra, S., Frenken, K., Hoekman, J., & van Oort, F. G. (2011). European infrastructure networks and regional innovation in science-based technologies. Economics of Innovation and New Technology, 20(5), 517-537. https://doi.org/10.1080/10438599.2011.562358
2010
Scholarly publications
Hoekman, J., Frenken, K., & Tijssen, R. J. W. (2010). Research collaboration at a distance: Changing spatial patterns of scientific collaboration within Europe. Research Policy, 39(5), 662-673. https://doi.org/10.1016/j.respol.2010.01.012
Professional publications
Frenken, K., Hoekman, J., & Hardeman, S. (2010). The globalisation of research collaboration. In World Social Science Report: Knowledge Divides (pp. 144-148). UNESCO.
2009
Scholarly publications
Hoekman, J., Frenken, K., & van Oort, F. G. (2009). The geography of collaborative knowledge production in Europe. Annals of Regional Science, 43(3), 721-738. https://doi.org/10.1007/s00168-008-0252-9
Frenken, K., Hoekman, J., Kok, S., Ponds, R. H. F., van Oort, F. G., & van Vliet, J. (2009). Death of distance in science? A gravity approach to research collaboration. In A. Pyka, & A. Scharnhorst (Eds.), Innovation Networks - New Approaches in Modelling and Analyzing (pp. 46-60). Springer.
https://dspace.library.uu.nl/bitstream/handle/1874/387455/Death_of_Distance_in_Science.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/387455/Death_of_Distance_in_Science.pdf?sequence=1
Frenken, K., Hardeman, S., & Hoekman, J. (2009). Spatial scientometrics: towards a cumulative research program. Journal of Informetrics, 3(3), 222-232. https://doi.org/10.1016/j.joi.2009.03.005
2007
Professional publications
Frenken, K., Hoekman, J., & van Oort, F. G. (2007). Towards a European Research Area. NAi Uitgevers/Ruimtelijk Planbureau.
2006
Scholarly publications
Frenken, K., & Hoekman, J. (2006). Convergence in an enlarged Europe: the role of network cities. Tijdschrift Voor Economische en Sociale Geografie, 97(3), 321-326. https://doi.org/10.1111/j.1467-9663.2006.00523.x
https://dspace.library.uu.nl/bitstream/handle/1874/387398/Convergence_in_an_enlarged_Europe.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/387398/Convergence_in_an_enlarged_Europe.pdf?sequence=1